The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomised double‐blind placebo‐controlled trial

Clare A. Whicher, Hermione C. Price, Peter Phiri, Shanaya Rathod, Katharine Barnard‐Kelly, Kandala Ngianga, Kerensa Thorne, Carolyn Asher, Robert C. Peveler, Joanne McCarthy, Richard I. G. Holt

Research output: Contribution to journalArticlepeer-review

Abstract

Background: People with severe mental illness are 2‐3 times more likely to be overweight and obese than the general population and this is associated with significant morbidity and premature mortality. This study investigated the feasibility and acceptability of using liraglutide 3.0 mg daily to address this problem.

Materials and Methods

Design: Double‐blind, randomised, placebo‐controlled pilot trial.

Setting: Mental health centres and primary care within Southern Health NHS Foundation Trust.

Participants: Adults with schizophrenia, schizoaffective, or first‐episode psychosis prescribed antipsychotic medication who were overweight or obese.

Intervention: Once daily subcutaneous liraglutide or placebo, titrated to 3.0 mg daily, for 6 months.

Primary outcome: recruitment, consent, retention and adherence.

Secondary exploratory outcomes: weight, HbA1c and Brief Psychiatric Rating Scale.

Results: 799 individuals were screened for eligibility. The commonest reasons for exclusion were ineligibility (44%) and inability to make contact (28%). The acceptance rate, as a proportion of all eligible participants, was 12.2%. The commonest stated reason why eligible candidates declined to participate related to the study specific medication and protocol (n= 50). 47 participants were randomised with 79% completing the trial. Participants in the liraglutide arm had lost a mean 5.7±7.9 kg compared with no significant weight change in the placebo group (treatment difference −6.0 kg, p=0.015). BMI, waist circumference and HbA1c reduced in the intervention group.

Conclusions: This study supports the need for a larger randomised controlled trial to evaluate use of liraglutide (maximum dose 3.0 mg daily) in the management of obesity in people with severe mental illness.
Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Early online date16 Feb 2021
DOIs
Publication statusEarly online - 16 Feb 2021

Keywords

  • schizophrenia
  • severe mental illness
  • obesity
  • overweight
  • liraglutide
  • feasibility
  • pilot

Fingerprint

Dive into the research topics of 'The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomised double‐blind placebo‐controlled trial'. Together they form a unique fingerprint.

Cite this